TITAN Trial: Reducing Phantom Limb Pain in People with Amputations
TITAN: a Randomised Controlled Trial Investigating the Effectiveness of Two Treatment Programs for Reducing Phantom Limb Pain Intensity and Its Interference with Function
Neuroscience Research Australia
208 participants
Dec 18, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to investigate the effectiveness of two rehabilitation programs for individuals who have undergone amputations and are experiencing phantom limb pain. The main question it aims to answer is: \- In individuals who have undergone amputations and are experiencing phantom limb pain, what is the effectiveness of a progressive rehabilitation program compared to a treatment program consisting of transcutaneous electrical nerve stimulation and cranial electrical stimulation on reducing pain intensity and pain interference? A total of 208 participants will be randomized into two groups: progressive rehabilitation program and stimulation devices. The progressive rehabilitation program includes pain science education, sensory training, and left/right judgements, imagined movements and mirror therapy. The treatment program for the group receiving the stimulation devices includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Both interventions will be delivered via eight, up to 1-hour telehealth sessions. Outcome measures will be assessed at baseline and weeks 12, 24 and 52.
Eligibility
Inclusion Criteria6
- Experiencing phantom limb pain for at least three months.
- Report at least one episode of phantom limb pain in the previous week.
- Report at least 4 points in pain intensity over the previous 7 days, assessed using the 11-point Numerical Pain Rating Scale.
- Be a resident in Australia for the intervention and follow-up period.
- Have access to the internet and smart device (e.g., mobile phone).
- Be proficient in English.
Exclusion Criteria9
- Bilateral amputation.
- Scheduled for major surgery during the study period.
- Pain in the intact limb.
- Vision impairment that would preclude successful participation.
- Auditory impairment that would preclude successful participation.
- Cognitive problems that would preclude effective participation in trial procedures (e.g., Alzheimer's, dementia).
- Previously diagnosed neurological disorders that affect the movement of the intact limb (e.g., stroke, Parkinson, Multiple Sclerosis).
- Completed Graded Motor Imagery in the order of left/right judgements, imagined movements, and mirror therapy.
- Have contraindications for the use of stimulation devices (e.g., pacemaker, spinal cord stimulator).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06167330